Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

40.63
-0.7300-1.76%
Pre-market: 40.790.1600+0.39%08:37 EDT
Volume:1.65M
Turnover:66.47M
Market Cap:2.98B
PE:-24.25
High:40.90
Open:40.90
Low:39.25
Close:41.36
52wk High:62.32
52wk Low:14.79
Shares:73.27M
Float Shares:61.73M
Volume Ratio:1.24
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6753
EPS(LYR):-1.8300
ROE:-15.31%
ROA:-11.00%
PB:3.33
PE(LYR):-22.20

Loading ...

TD Cowen Remains a Buy on Enliven Therapeutics (ELVN)

TIPRANKS
·
Yesterday

Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial

MT Newswires Live
·
Oct 07

Enliven Therapeutics Announces FDA Alignment on Enable-2 Phase 3 Trial Design for Relcobatinib (Elvn-001) in Previously Treated Chronic Myeloid Leukemia

THOMSON REUTERS
·
Oct 07

Enliven Therapeutics - on Track to Initiate Enable-2 Phase 3 Trial Before Year-End 2026

THOMSON REUTERS
·
Oct 07

Enliven Therapeutics Director Garland J. Scott Disposes of $606,719 in Common Shares

Reuters
·
Oct 06

Enliven initiated with an Overweight at Morgan Stanley

TIPRANKS
·
Oct 02

Enliven Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $75

THOMSON REUTERS
·
Oct 01

Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 250,000 in Common Shares

Reuters
·
Sep 22

Enliven Therapeutics Management to Attend Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 04

Enliven Therapeutics to Present Phase 1 Enable Trial Data for ELVN-001 in CP-CML at SOHO 2026

Reuters
·
Sep 01

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (Soho) 2026 Annual Meeting

THOMSON REUTERS
·
Sep 01

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

TIPRANKS
·
Aug 24

Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17

Reuters
·
Aug 20

Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62

THOMSON REUTERS
·
Aug 18

Enliven initiated with an Outperform at William Blair

TIPRANKS
·
Aug 18

Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating

THOMSON REUTERS
·
Aug 18

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Aug 13

Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares

Reuters
·
Aug 07

Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)

TIPRANKS
·
Aug 06